Business · 07/12/2011
FDA Announces Public Meeting to Discuss Biosimilar User Fee Program
The Food and Drug Administration (FDA) is hosting a public meeting to gather feedback on proposed recommendations for a user fee program for biosimilar biological products from FYs 2013 to 2017.
Original source language: Federal Register — Health and Human ServicesOpen original release →